Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
|Videos|May 6, 2022
1969
Author(s)Richard M. Berlin, MD
"...we came in peace for all mankind. Then returned to continue the war."
Advertisement
Any Good Poem
Richard Berlin, MD, shares Alex Dimitrov's poem "
Dr Berlin has been writing a poem about his experience of being a doctor every month for the past 24 years inPsychiatric Times™. He is instructor in psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts. His latest book is
Advertisement
Related to this article
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Check out our pipeline updates from October!
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
2
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
3
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
4
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
5